Market News AIOpen the app

Cardiff Oncology got FDA Fast Track approval for its drug onvansertib to treat a type of colon cancer.

TrialRead the original at globenewswire.com
Good for CRDF

The FDA designation and higher response rate support faster development and review. The drug is still in a Phase 2 study, but the results and planned next trial make this positive news for Cardiff.

CRDF · Cardiff Oncology, Inc.

AI read · Good for CRDF

The AI's read

The designation may help Cardiff develop the treatment and move its review along faster. The trial result supports further testing. The drug is still being studied, so this news does not mean it is approved for patients.

Get alerts for CRDF

Follow Cardiff Oncology, Inc. (CRDF) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CRDF
Free on the App Store and Google Play, or on the web.